Search Results

Cook Medical Enrolls First Patient in ZFEN+ Clinical Study

January 31, 2024—Cook Medical announced that the first patient was treated in the clinical study of the company’s Zenith Fenestrated+ (ZFen+) endovascular graft in the United States.

Fenestrated-Branched EVAR Assessed in Complex Aortic Aneurysm

March 16, 2022—The Society for Vascular Surgery (SVS) announced findings from a study assessing the incidence of intraoperative adverse events and their impact on outcomes of fenestrated-branched endovascular aneurysm repair (FB-EVAR) for the treatment of complex aortic aneurysms.

First Implant Completed in Thoracoabdominal Aortic Aneurysm Clinical Study of Gore Excluder Device

January 12, 2016—Gore & Associates announced the first implant in the United States of the Gore Excluder thoracoabdominal branch endoprosthesis in a clinical study for the treatment of aortic aneurysms involving the visceral branch vessels.

Gore Launches Excluder Conformable AAA Endoprosthesis With Active Control System

March 30, 2021—Gore & Associates, Inc. announced the first use of the FDA-approved Excluder conformable abdominal aortic aneurysm (AAA) endoprosthesis with Active Control system in cases outside of clinical trials.

Cook Zenith Fenestrated+ Endovascular Graft Pivotal Study Completes Enrollment

August 28, 2025—Cook Medical announced that the final patient has been enrolled in the global clinical study of the company’s investigational Zenith Fenestrated+ endovascular graft (ZFen+), marking completion of recruitment in the pivotal study.

Cook Medical’s ZFen+ Endovascular Graft Receives IDE Approval for Aortic Aneurysm Study

June 26, 2023—Cook Medical announced that it received approval from the FDA to initiate an investigational device exemption study of the company’s Zenith Fenestrated+ (ZFen+) endovascular graft.

Study Finds Mortality and Rupture Are Uncommon After Elective FB-EVAR of Asymptomatic, Intact Thoracoabdominal Aortic Aneurysms

December 9, 2024—In a multicenter, prospective, nonrandomized study evaluating outcomes of fenestrated-branched endovascular aortic repair (FB-EVAR) in patients with asymptomatic, intact thoracoabdominal aortic aneurysms (TAAAs), Oderich et al found that the procedure was effective out to 5 years, with a low incidence of early and late aortic-related mortality (ARM) and aortic rupture.